Centessa Pharmaceuticals plc ADR’s recently made public that its Chief Executive Officer SAHA SAURABH unloaded Company’s shares for reported $0.7 million on May 20 ’25. In the deal valued at $12.71 per share,55,000 shares were sold. As a result of this transaction, SAHA SAURABH now holds 221,017 shares worth roughly $2.92 million.
Then, SAHA SAURABH bought 55,000 shares, generating $700,700 in total proceeds.
Before that, GOYAL ARJUN bought 417,646 shares. Centessa Pharmaceuticals plc ADR shares valued at $5,315,005 were divested by the Director at a price of $12.73 per share. As a result of the transaction, GOYAL ARJUN now holds 462,585 shares, worth roughly $6.11 million.
Chardan Capital Markets initiated its Centessa Pharmaceuticals plc ADR [CNTA] rating to a Buy in a research note published on May 08, 2025; the price target was $30. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late March with a ‘”an Overweight”‘ rating. TD Cowen began covering CNTA with “Buy” recommendation on January 07, 2025. Morgan Stanley revised its rating on September 20, 2024. It rated CNTA as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of CNTA
On Tuesday, Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] saw its stock jump 7.67% to $13.20. Over the last five days, the stock has gained 5.94%. Centessa Pharmaceuticals plc ADR shares have fallen nearly -21.19% since the year began. Nevertheless, the stocks have risen 47.49% over the past one year. While a 52-week high of $19.09 was reached on 02/07/25, a 52-week low of $7.75 was recorded on 04/09/25. SMA at 50 days reached $13.62, while 200 days put it at $15.21.
Levels Of Support And Resistance For CNTA Stock
The 24-hour chart illustrates a support level at 12.49, which if violated will result in even more drops to 11.77. On the upside, there is a resistance level at 13.63. A further resistance level may holdings at 14.05. The Relative Strength Index (RSI) on the 14-day chart is 52.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 46.30%. Stochastics %K at 32.56% indicates the stock is a holding.
The most recent change occurred on September 19, 2024 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
